Anti-NGF Studies Face Major Redesign After Arthritis Advisory Cmte. Urges Resumed Testing
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer’s tanezumab, Regeneron’s REGN475 and Janssen’s fulranumab could head back to the clinic soon, but will need radical protocol changes to protect patients from the emerging risk of joint destruction.